Featured Research

from universities, journals, and other organizations

Closing In On A Vaccine For Breast Cancer

Date:
March 14, 2005
Source:
Washington University School Of Medicine
Summary:
Progress toward development of a breast cancer vaccine has been reported by researchers at Washington University School of Medicine and the Siteman Cancer Center in St. Louis.

Mammograms could more frequently bear good news if researchers develop an effective breast cancer vaccine.
Credit: Photo courtesy of Washington University School Of Medicine

Progress toward development of a breast cancer vaccine has been reported by researchers at Washington University School of Medicine and the Siteman Cancer Center in St. Louis.

Cancer-fighting vaccines stimulate immune cells to recognize tumor cells as foreign and destroy them. Physicians believe a vaccine-induced immune response could be used to supplement other cancer therapies or to immunize high-risk people against cancer.

"We've been studying a protein called mammaglobin-A found in 80 percent of breast tumors," says Thalachallour Mohanakumar, Ph.D., the Jacqueline G. and William E. Maritz Professor of Immunology and Oncology in the Department of Surgery and at the Siteman Cancer Center. "The protein is especially interesting for cancer immunotherapy because of its frequent occurrence and because breast tumors express it at high levels."

In articles in the Journal of the National Cancer Institute and Breast Cancer Research and Treatment, the researchers report that they constructed a vaccine consisting of copies of the DNA sequence that makes mammaglobin-A in humans.

The researchers theorized the DNA vaccine would rev up special immune cells called T cells to recognize mammaglobin-A as a foreign molecule when it is displayed on the surface of cells as an antigen (a small protein that the immune system may recognize). The primed T-cells then would proliferate and attack when they met with mammaglobin-A antigens.

"Mammaglobin-A is involved in breast development and secreted in breast milk," Mohanakumar says. "So we had to prove first that we could elicit an immune response to a protein that is in the body normally."

They injected the DNA vaccine under the skin of test mice that had been engineered so that their immune systems would react to the human mammaglobin-A like a human immune system. The researchers loaded specific cells in the mice with mammaglobin-A antigens and found that the vaccine-primed T-cells attacked those loaded cells.

The research team also transferred vaccine-primed T cells into mice with growing tumors that had or didn't have mammaglobin-A antigens. Tumors with mammaglobin-A antigens stopped growing and shrunk in volume, while those without the antigens continued to grow at the usual pace.

"The results demonstrated that the vaccine-primed immune response is specific to mammaglobin-A antigens," Mohanakumar says.

Breast tumors with mammaglobin-A antigens on their surface also may display antigens that come from multiple parts of the mammaglobin-A molecule. Further experiments confirmed the importance of generating T cells that can react to a variety of different mammaglobin-A antigens.

When the research team tested a DNA vaccine containing the DNA code for just one part of the mammaglobin-A molecule, they found T cells reacting to only that antigen, indicating that the method can generate immune cells that target specific parts of the mammaglobin-A protein.

"Now that we've found how effectively an immune response can be generated to mammaglobin-A, we plan to conduct clinical trials in patients who are at very high risk for breast cancer and in patients who have had a relapse after initial treatment," Mohanakumar says. "We want to see if giving patients the DNA vaccine can prevent or eliminate breast cancer or at least slow its growth."

###

Narayanan K, Jaramillo A, Benshoff ND, Campbell LC, Fleming TP, Dietz, JR, Mohanakumar T. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. Journal of the National Cancer Institute 2004 Sept 15;96(18):1388-1396.

Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8 cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Research and Treatment 2004; 88:29-41.

Funding from the Susan G. Komen Breast Cancer Foundation supported this research.


Story Source:

The above story is based on materials provided by Washington University School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Washington University School Of Medicine. "Closing In On A Vaccine For Breast Cancer." ScienceDaily. ScienceDaily, 14 March 2005. <www.sciencedaily.com/releases/2005/03/050308132652.htm>.
Washington University School Of Medicine. (2005, March 14). Closing In On A Vaccine For Breast Cancer. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2005/03/050308132652.htm
Washington University School Of Medicine. "Closing In On A Vaccine For Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2005/03/050308132652.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins